Theralase Technologies Inc. V.TLT

This is good!

[Hankerchief]

The Company is planning to commence toxicology studies withRutherrin® to determine the maximum recommended human doseof the drug, when administered systemically into the human body,via intravenous injections. Due to the limitations of using laser light to activate Rutherrin® indeep oncological targets, Theralase’s research strongly suggeststhat Rutherrin® may be activated with radiation therapy, which isable to increase the ‘tumour’s damage zone’ and the effectivenessof the anti-cancer therapy beyond the reach of light in the body.


Finally something about actually making progress with IV Rutherrin and xray activation!!  "Planning to commence" needs to be soon, very soon IMO.

[RichieRich123]

Based on what is in the QTLY update I think that Mgmt. definitely reads this Board (for sure).

[robertshaw]

But the idiot management has a history to call more than 3 years as "immediate future"

[Hankerchief]

Yep.  Maybe this time will be different.  I really think the IV + Xray activation could really be a huge benefit.

[TriumphSpitSix]

Of course it would be a huge benefit. It would increase the kinds of cancers they can treat which are currently "out of range" due to the 3-4 inch maximum penetration of laser light.

[Quattro74]

I think that TLT will work on other DFOC devices for other indications that can be applied topically(intravesical). Every one of these type cancers will be a little different. The complex ones seem to be accounted for, TLT may have solved nmibc. Lumeda/Medtronic nsclc. Yet this new tech using IV + XRay will work on all solid tumor cancers. Should be huge, maybe 60 Minutes will call it a 'cure&